Skip to main

Impact case study database

The impact case study database allows you to browse and search for impact case studies submitted to the REF 2021. Use the search and filters below to find the impact case studies you are looking for.
Impact case study database FAQs
Download all impact case studies (spreadsheet)
Download all impact case studies (spreadsheet) (generating)
Download all impact case study tags (spreadsheet)
Download all impact case study tags (spreadsheet) (generating)
Back

Clinical development of olaparib, a PARP inhibitor, leading to improved outcomes for cancer patients

Download case study PDF
Submitting institution
Institute of Cancer Research: Royal Cancer Hospital (The)
Unit of assessment
1 - Clinical Medicine
Summary impact type
Health
Request cross-referral to
-
Is this case study continued from a case study submitted in 2014?
No
Underpinning research subjects
  • Clinical Sciences
  • Oncology And Carcinogenesis
  • Public Health And Health Services

1. Summary of the impact

2. Underpinning research

3. References to the research

4. Details of the impact

5. Sources to corroborate the impact

Additional contextual information

Grant funding

Grant number Value of grant
C51/A6883 £3,835,960
A7401 £3,767,251
None given (ECMC 2007) £1,250,000
C12540/A15573 £750,000
None given (ECMC 2012) £750,000
C12540/A25128 £1,282,041
None given (ECMC 2017) £1,282,041
None given (BRC 2007) £46,800,000
BRC-2011-10059 £61,543,735
IS-BRC-1215-20021 £43,074,315
BBC024X (internal) £30,872,915
C1178/A7851 £2,302,100
C12540/A12829 £231,601
C12540/A13230 £282,970
C1491/A9895 £5,010,603
C1491/A15955 £5,901,462
SU2C-AACR-DT0712 £6,312,000
PG14-010-TR2 £315,895
TLD-S15-006 £103,923
MRC­CRTF13­001 £250,686
CEO13_2­002 £6,454,883
PIIF-GA-2013-625792 £197,754
PCF­16YOUN11 £142,020
C12540/A20447 £236,883
C1491/A25351 £6,456,485
C347/A15403 £11,023,183
C309/A25144 £21,523,238
Countries
  • USA
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • Iceland
  • Liechtenstein
  • Norway
  • UK
  • Canada
  • Japan
  • Brazil
  • Australia
  • China
  • Israel
  • South Korea
  • Russia
  • Argentina
  • Taiwan
  • Turkey
Formal partners
  • The Royal Marsden NHS Foundation Trust
  • Stand Up to Cancer - Prostate Cancer Foundation Prostate Dream Team
  • KuDOS
  • AstraZeneca
  • Merck Sharp and Dohme
Funding programmes
  • Cancer Research UK: Funding to the Section of Medicine (2006 to 2011)
  • Cancer Research UK: Experimental Cancer Medicine Centre (2007)
  • Department of Health: Experimental Cancer Medicine Centre (2007)
  • Cancer Research UK: Experimental Cancer Medicine Centre (2012)
  • Department of Health: Experimental Cancer Medicine Centre (2012)
  • Cancer Research UK: Experimental Cancer Medicine Centre (2017)
  • Department of Health: Experimental Cancer Medicine Centre (2017)
  • The National Institute for Health Research Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (2007)
  • The National Institute for Health Research Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (2011)
  • The National Institute for Health Research Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (2017)
  • Breakthrough Breast Cancer (now Breast Cancer Now) Centre Core Grant 2003 to 2010
  • Cancer Research UK: Chair of Medical Oncology
  • Cancer Research UK: CRUK/11/029: TO-PARP: Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer
  • Cancer Research UK: Identification and Molecular Characterisation of metastatic sporadic castration resistant prostate cancers (mCRPC)
  • Cancer Research UK: ICR Clinical Trials and Statistic Unit Programme Grant (2008 to 2013)
  • Cancer Research UK: ICR Clinical Trials and Statistic Unit Programme Grant (2013 to 2018)
  • Stand Up To Cancer : Prostate Dream Team Translational Cancer Research Grant - Precision Therapy of Advanced Prostate Cancer
  • Prostate Cancer UK: Developing an analytically validated biomarker assay to identify patients with BRCAness who will benefit from treatment with PARP inhibitors or platinum therapy
  • Prostate Cancer UK: Integrative prostate cancer genomics to improve castration-resistant prostate cancer treatment by molecular stratification
  • Medical Research Council: Predictive biomarkers of response to DNA repair targeting agents in sporadic prostate cancer
  • Prostate Cancer UK: London Movember Centre of Excellence
  • European Commission: Marie Skłodowska-Curie Individual Fellowship - CDELP
  • Prostate Cancer Foundation: Defining the landscape and clinical relevance of ATM defects in lethal prostate cancer
  • Cancer Research UK: TOPARP - Phase II
  • Cancer Research UK: ICR Clinical Trials and Statistic Unit Programme Grant (2018-2023)
  • Cancer Research UK: CRUK Centre at ICR and Royal Marsden (2012)
  • Cancer Research UK: CRUK Centre at ICR and Royal Marsden (2016)
Global research identifiers
  • grid.11485.39
  • grid.57981.32
  • grid.451056.3
  • grid.458394.7
  • grid.430427.6
  • grid.453276.1
  • grid.420006.0
  • grid.270680.b
  • grid.453146.1
Name of funders
  • Cancer Research UK
  • Department of Health
  • National Institute for Health Research
  • Breakthrough Breast Cancer (now Breast Cancer Now)
  • Stand Up To Cancer (part of the Entertainment Industry Foundation)
  • Prostate Cancer UK
  • Medical Research Council
  • European Commission
  • Prostate Cancer Foundation
Researcher ORCIDs
  • 0000-0002-2034-595X
  • 0000-0001-5999-5020
  • 0000-0003-1446-7878
  • 0000-0002-3698-6241
  • 0000-0002-4811-7983
  • 0000-0002-3226-0515
  • 0000-0001-8715-2901
  • 0000-0001-8666-1608